Marvin R. Garovoy
Corporate Officer/Principal at American Board of Internal Medicine
Profile
Marvin R.
Garovoy is the founder of AceLink Therapeutics, Inc. (founded in 2018).
He is currently a Member of the American Board of Internal Medicine.
Dr. Garovoy's former positions include Head-Clinical Science at Avid Bioservices, Inc., Chief Medical Officer at Arriva Pharmaceuticals, Inc., Professor at The University of California, San Francisco, Chief Medical Officer at Aevi Genomic Medicine, Inc. (2012-2013), and Vice President-Clinical Science at XOMA (US) LLC.
Dr. Garovoy received his undergraduate degree from New York University and his doctorate from The State University of New York.
Marvin R. Garovoy active positions
Companies | Position | Start |
---|---|---|
American Board of Internal Medicine
American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron. | Corporate Officer/Principal | - |
Former positions of Marvin R. Garovoy
Companies | Position | End |
---|---|---|
AEVI GENOMIC MEDICINE, INC. | Chief Tech/Sci/R&D Officer | 2013-12-30 |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Chief Tech/Sci/R&D Officer | 2011-01-18 |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Founder | - |
AVID BIOSERVICES, INC. | Chief Tech/Sci/R&D Officer | - |
The University of California, San Francisco | Corporate Officer/Principal | - |
Training of Marvin R. Garovoy
New York University | Undergraduate Degree |
The State University of New York | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
AVID BIOSERVICES, INC. | Health Technology |
Private companies | 5 |
---|---|
American Board of Internal Medicine
American Board of Internal Medicine Miscellaneous Commercial ServicesCommercial Services The American Board of Internal Medicine operates as a self-appointed physician evaluation organization. The private company is based in Philadelphia, PA. The CEO of the company is Richard J. Baron. | Commercial Services |
XOMA (US) LLC
XOMA (US) LLC Pharmaceuticals: MajorHealth Technology XOMA (US) LLC develops pharmaceutical preparations. It offers proprietary drugs and toiletries. The company is headquartered in Emeryville, CA. | Health Technology |
Arriva Pharmaceuticals, Inc.
Arriva Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Arriva Pharmaceuticals is a privately held biopharmaceutical company focused on developing anti-inflammatory therapies for treating respiratory diseases. The company's areas of therapeutic focus are: hereditary emphysema, Chronic Obstructive Pulmonary Disease (COPD) including smoking-related emphysema, cystic fibrosis and other respiratory indications. Arriva’s current clinical focus is the development of Respriva™, its nebulized, recombinant alpha 1-antitrypsin for hereditary emphysema. Arriva Pharmaceuticals, Inc., is located in Alameda, California. | Health Technology |
Aevi Genomic Medicine, Inc.
Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
AceLink Therapeutics, Inc.
AceLink Therapeutics, Inc. BiotechnologyHealth Technology AceLink Therapeutics, Inc. is a biopharmaceutical startup founded in 2018 that focuses on developing safe and effective medicines to address genetic diseases with high unmet needs. AceLink Therapeutics is based in Newark, CA. The private company's initial focus is on developing novel therapeutics for Fabry disease and type 1 Gaucher disease. The company was founded in 2018 by Wen Chen, Marvin R. Garovoy, and Jerry Shen. Jerry Shen has been the CEO since 2018. | Health Technology |
- Stock Market
- Insiders
- Marvin R. Garovoy